A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 18 Jan 2023
At a glance
- Drugs HLX 23 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shanghai Henlius Biotech
- 13 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Oct 2022 Planned End Date changed from 1 Nov 2023 to 1 Mar 2024.
- 21 Oct 2022 Planned primary completion date changed from 1 Jul 2022 to 15 May 2023.